Home › Therapeutic areas › Neurology
Neurology (89 companies · 63 conditions)
Conditions
Multiple Sclerosis 17 Amyotrophic Lateral Sclerosis 16 Rare Alzheimer's Disease 14 Major Depressive Disorder 13 Parkinson's Disease 13 Duchenne Muscular Dystrophy 10 Rare Epilepsy 8 Schizophrenia 8 Bipolar Disorder 7 Myasthenia Gravis 7 Rare Huntington's Disease 6 Rare Frontotemporal Dementia 5 Rare Generalized Anxiety Disorder 5 Friedreich's Ataxia 4 Rare Lewy Body Dementia 4 Migraine 4 Multiple System Atrophy 4 Rare Myotonic Dystrophy 4 Rare Attention Deficit Hyperactivity Disorder 3 Autism Spectrum Disorder 3 Chronic Pain 3 Dravet Syndrome 3 Rare Post-Traumatic Stress Disorder 3 Rett Syndrome 3 Rare Substance Use Disorder 3 Facioscapulohumeral Muscular Dystrophy 2 Rare Infantile Spasms 2 Rare Narcolepsy 2 Rare Progressive Supranuclear Palsy 2 Rare Spinal Cord Injury 2 Stiff Person Syndrome 2 Rare Tourette Syndrome 2 Acute Pain 1 Aneurysmal Subarachnoid Hemorrhage 1 Angelman Syndrome 1 Rare Anorexia Nervosa 1 Charcot-Marie-Tooth Disease Type 2S 1 Rare Chronic Inflammatory Demyelinating Polyneuropathy 1 Rare Chronic Low Back Pain 1 CLN2 Batten Disease 1 Rare Cocaine Use Disorder 1 Delayed Sleep Phase Disorder 1 Dementia-Related Psychosis 1 Essential Tremor 1 Fragile X Syndrome 1 Rare Giant Axonal Neuropathy 1 Rare GNE Myopathy 1 Rare Guillain-Barré Syndrome 1 Insomnia 1 Ischemic Stroke 1 Jet Lag Disorder 1 Lennox-Gastaut Syndrome 1 Rare Limb-Girdle Muscular Dystrophy 1 Rare Motion Sickness 1 Non-24-Hour Sleep-Wake Disorder 1 Non-Fluent Variant Primary Progressive Aphasia 1 Rare Primary Periodic Paralysis 1 Rare Smith-Magenis Syndrome 1 Rare Spinal Bulbar Muscular Atrophy 1 Rare Spinal Muscular Atrophy 1 Rare Spinocerebellar Ataxia 1 Rare Tuberous Sclerosis Complex 1 Rare X-Linked Adrenoleukodystrophy 1 Rare
Companies
| Ticker | Company | Therapeutic areas | In Neurology | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AARD | Aardvark Therapeutics | DermatologyMetabolic+1 Rare | 1 | Phase 3 | $25.2M | 3 |
| ACIU | AC Immune | Neurology Rare | 10 | Phase 3 | $210M | 11 |
| ABOS | Acumen Pharmaceuticals | Neurology | 4 | Phase 2 | $16.6M | 4 |
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 1 | Phase 1 | $26.0M | 8 |
| ATHE | Alterity Therapeutics | Neurology Rare | 2 | Phase 2 | $35.7M | 2 |
| ALT | Altimmune | GI/HepatologyMetabolic+1 | 1 | Phase 3 | $298M | 3 |
| ANRO | Alto Neuroscience | Neurology | 6 | Phase 2 | $999M | 6 |
| ALMS | Alumis | DermatologyImmunology+1 | 1 | Phase 3 | $628M | 5 |
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 1 | Phase 3 | $3.54B | 5 |
| ANNX | Annexon | HematologyNeurology+2 Rare | 3 | Phase 3 | $662M | 6 |
| ARVN | Arvinas | NeurologyOncology Rare | 3 | Approved | $447M | 10 |
| ATAI | Atai Beckley | Neurology | 5 | Phase 2 | $2.73B | 5 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 1 | Approved | $290M | 12 |
| AXSM | Axsome Therapeutics | Neurology Rare | 10 | Approved | $7.15B | 15 |
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | 1 | Phase 2 | $220M | 8 |
| CAPR | Capricor Therapeutics | Infectious DiseaseNeurology Rare | 1 | NDA Submitted | $489M | 2 |
| RNAC | Cartesian Therapeutics | ImmunologyNeurology+1 Rare | 1 | Phase 3 | $187M | 4 |
| CRVO | CervoMed | Neurology Rare | 4 | Phase 2 | $22.7M | 4 |
| CING | Cingulate | Neurology | 1 | NDA Submitted | $70.6M | 1 |
| CLNN | Clene | Neurology Rare | 3 | NDA Submitted | $46.4M | 5 |
| CGTX | Cognition Therapeutics | Neurology | 2 | Phase 2 | $59.9M | 2 |
| CMPS | COMPASS Pathways | Neurology | 3 | NDA Submitted | $1.13B | 3 |
| CTNM | Contineum Therapeutics | NeurologyRespiratory Rare | 3 | Phase 2 | $375M | 4 |
| COYA | Coya Therapeutics | Neurology Rare | 2 | Phase 2 | $70.8M | 6 |
| CYDY | CytoDyn | NeurologyOncology | 1 | Phase 2 | $367M | 3 |
| DFTX | Definium Therapeutics | Neurology | 4 | Phase 3 | $4.02B | 4 |
| DYN | Dyne Therapeutics | MetabolicNeurology Rare | 7 | NDA Submitted | $3.00B | 10 |
| ELDN | Eledon Pharmaceuticals | ImmunologyMetabolic+1 Rare | 1 | Phase 2 | $167M | 3 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+2 | 1 | Approved | $253M | 8 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 2 | Approved | $1.84B | 17 |
| EVMN | Evommune | DermatologyImmunology+1 | 1 | Phase 2 | $290M | 6 |
| FBIO | Fortress Biotech | DermatologyHematology+4 Rare | 1 | Approved | $61.4M | 16 |
| GANX | Gain Therapeutics | MetabolicNeurology Rare | 4 | Phase 1 | $52.5M | 5 |
| GHRS | GH Research | NeurologyWomen's Health | 3 | Phase 2 | $1.25B | 4 |
| GRCE | Grace Therapeutics | Neurology | 1 | NDA Submitted | $36.2M | 1 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | 12 | Approved | $1.94B | 17 |
| HELP | Helus Pharma | Neurology | 3 | Phase 3 | $575M | 3 |
| IMUX | Immunic | GI/HepatologyNeurology | 2 | Phase 3 | $116M | 4 |
| IMVT | Immunovant | ImmunologyNeurology Rare | 2 | Phase 3 | $6.87B | 4 |
| IXHL | Incannex Healthcare | NeurologyRespiratory | 1 | Phase 2 | $21.8M | 2 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 2 | Approved | $26.7B | 15 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 7 | Approved | $4.49B | 29 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 1 | Phase 2 | $60.7M | 13 |
| KROS | Keros Therapeutics | NeurologyOncology Rare | 2 | Phase 3 | $222M | 5 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 3 | NDA Submitted | $297M | 6 |
| LRMR | Larimar Therapeutics | Neurology Rare | 1 | NDA Submitted | $313M | 1 |
| LBRX | LB Pharmaceuticals | Neurology | 3 | Phase 3 | $1.30B | 3 |
| LXEO | Lexeo Therapeutics | CardiovascularNeurology Rare | 9 | Phase 2 | $236M | 12 |
| LCTX | Lineage Cell Therapeutics | MetabolicNeurology+1 Rare | 2 | Phase 2 | $207M | 13 |
| LGVN | Longeveron | CardiovascularNeurology Rare | 1 | Phase 2 | $7.1M | 3 |
| MPLT | MapLight Therapeutics | Neurology | 3 | Phase 2 | $365M | 3 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 2 | Phase 3 | $827M | 16 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | 2 | Approved | $1.54B | 5 |
| NGEN | NervGen Pharma | Neurology | 3 | Phase 3 | $211M | 3 |
| NGNE | Neurogene | Neurology Rare | 1 | Phase 3 | $478M | 1 |
| NRSN | NeuroSense Therapeutics | Neurology Rare | 3 | Phase 2 | $2.9M | 3 |
| NAMS | NewAmsterdam Pharma | CardiovascularMetabolic+1 | 1 | NDA Submitted | $2.33B | 6 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | 1 | Phase 1 | $89.6M | 8 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 10 | Approved | $109M | 11 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.56B | 13 |
| OCS | Oculis Holding | NeurologyOphthalmology Rare | 1 | Phase 3 | $418M | 5 |
| OMER | Omeros | HematologyNeurology+2 Rare | 2 | Approved | $1.04B | 6 |
| OVID | Ovid Therapeutics | Neurology Rare | 3 | Phase 2 | $419M | 4 |
| KTTA | Pasithea Therapeutics | NeurologyOncology Rare | 2 | Phase 1 | $16.0M | 4 |
| PEPG | PepGen | Neurology Rare | 1 | Phase 2 | $269M | 1 |
| DTIL | Precision Biosciences | Infectious DiseaseMetabolic+1 Rare | 2 | Phase 1 | $197M | 5 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 1 | Phase 2 | $4.8M | 7 |
| PMN | ProMIS Neurosciences | Neurology Rare | 7 | Phase 1 | $28.9M | 9 |
| PRQR | ProQR Therapeutics | MetabolicNeurology Rare | 1 | Phase 1 | $163M | 7 |
| RAPP | Rapport Therapeutics | Neurology | 4 | Phase 3 | $1.41B | 6 |
| RLMD | Relmada Therapeutics | MetabolicNeurology+1 Rare | 2 | Phase 2 | $321M | 4 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+3 Rare | 7 | Phase 3 | $4.7M | 11 |
| SRPT | Sarepta Therapeutics | NeurologyRespiratory Rare | 10 | Approved | $1.58B | 11 |
| SLDB | Solid Biosciences | CardiovascularNeurology Rare | 2 | Phase 3 | $695M | 6 |
| STOK | Stoke Therapeutics | Neurology Rare | 1 | Phase 3 | $1.73B | 2 |
| TSHA | Taysha Gene Therapies | Neurology Rare | 3 | Phase 3 | $1.30B | 4 |
| TGTX | Tg Therapeutics | Neurology Rare | 6 | Approved | $9.48B | 6 |
| TLSA | Tiziana Life Sciences | ImmunologyNeurology Rare | 4 | Phase 2 | $83.2M | 5 |
| RARE | Ultragenyx Pharmaceutical | CardiovascularMetabolic+1 Rare | 1 | Approved | $1.70B | 10 |
| QURE | uniQure | HematologyMetabolic+1 Rare | 2 | Approved | $1.46B | 4 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 16 | Approved | $230M | 27 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | 1 | Phase 3 | $3.43B | 9 |
| VOR | Vor Biopharma | ImmunologyNeurology Rare | 1 | Phase 3 | $1.12B | 2 |
| VYGR | Voyager Therapeutics | MetabolicNeurology Rare | 8 | Phase 1 | $94.6M | 9 |
| WVE | Wave Life Sciences | MetabolicNeurology+1 Rare | 2 | Phase 2 | $560M | 5 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.59B | 28 |
| XENE | Xenon Pharmaceuticals | Neurology Rare | 8 | NDA Submitted | $3.81B | 9 |
| XERS | Xeris Biopharma | MetabolicNeurology Rare | 1 | Approved | $3.07B | 4 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 3 | NDA Submitted | $1.88B | 11 |
No companies match.